CNS Pharmaceuticals, Inc. Increase (Decrease) in Accrued Liabilities
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Accrued Liabilities of -$568.25 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-08-14
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was -$593.09K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-03-31 was $24.84K, a 69.73% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was $628.39K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was -$76.57K, a 154.48% decline year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $603.44K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was -$294.86K, a 159.17% decline from fiscal 2020.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2020 was $498.30K, a 1133.61% increase from fiscal 2019.
- CNS Pharmaceuticals, Inc. increase (decrease) in accrued liabilities for fiscal 2019 was $40.39K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$593.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$568.25K 10-Q · filed 2023-08-14 | $60.14K derived: sum of 3 quarters · filed 2023-08-14 | -$16.44K derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | $24.84K 10-Q · filed 2023-05-15 | $653.23K derived: sum of 2 quarters · filed 2023-05-15 | $576.65K derived: sum of 3 quarters · filed 2023-05-15 | $546.22K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-12-31 | $628.39K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $551.82K derived: sum of 2 quarters · filed 2023-03-31 | $521.38K derived: sum of 3 quarters · filed 2023-08-14 | $603.44K 10-K · filed 2023-03-31 |
| 2022-09-30 | -$76.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$107.01K derived: sum of 2 quarters · filed 2023-08-14 | -$24.95K 10-Q · filed 2022-11-10 | -$701.22K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-06-30 | -$30.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $51.62K 10-Q · filed 2023-08-14 | -$624.65K derived: sum of 3 quarters · filed 2023-08-14 | -$484.11K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $82.06K 10-Q · filed 2023-05-15 | -$594.21K derived: sum of 2 quarters · filed 2023-05-15 | -$453.67K derived: sum of 3 quarters · filed 2023-05-15 | -$227.93K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$676.27K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$535.73K derived: sum of 2 quarters · filed 2023-03-31 | -$309.99K derived: sum of 3 quarters · filed 2023-03-31 | -$294.86K 10-K · filed 2023-03-31 |
| 2021-09-30 | $140.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $366.28K derived: sum of 2 quarters · filed 2022-11-10 | $381.42K 10-Q · filed 2022-11-10 | $640.62K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $225.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $240.87K 10-Q · filed 2022-08-12 | $500.08K derived: sum of 3 quarters · filed 2022-08-12 | $649.99K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $15.14K 10-Q · filed 2022-05-13 | $274.34K derived: sum of 2 quarters · filed 2022-05-13 | $424.25K derived: sum of 3 quarters · filed 2022-05-13 | $390.15K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $259.20K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $409.11K derived: sum of 2 quarters · filed 2022-03-03 | $375.01K derived: sum of 3 quarters · filed 2022-03-03 | $498.30K 10-K · filed 2022-03-03 |
| 2020-09-30 | $149.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $115.81K derived: sum of 2 quarters · filed 2021-11-12 | $239.10K 10-Q · filed 2021-11-12 | $257.02K derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$34.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $89.19K 10-Q · filed 2021-08-13 | $107.12K derived: sum of 3 quarters · filed 2021-08-13 | $117.19K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $123.29K 10-Q · filed 2021-05-13 | $141.22K derived: sum of 2 quarters · filed 2021-05-13 | $151.30K derived: sum of 3 quarters · filed 2021-05-13 | $158.98K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $17.92K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $28.00K derived: sum of 2 quarters · filed 2021-02-12 | $35.69K derived: sum of 3 quarters · filed 2021-02-12 | $40.39K 10-K · filed 2021-02-12 |
| 2019-09-30 | $10.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $17.76K derived: sum of 2 quarters · filed 2020-11-12 | $22.47K 10-Q · filed 2020-11-12 | $33.10K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $7.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $12.39K 10-Q · filed 2020-08-10 | $23.02K derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | $4.71K 10-Q · filed 2020-05-15 | $15.34K derived: sum of 2 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $10.63K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$6.24K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | -$16.88K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |